From GlobeNewswire: 2025-04-03 18:58:00

Mesoblast reassures that its allogeneic cellular products, including Ryoncil® and Revascor®, will not be subject to U.S. Government tariffs. Ryoncil® is an FDA-approved therapy for pediatric patients with steroid-refractory acute graft versus host disease, designated as a U.S. origin product. Mesoblast is a global leader in developing off-the-shelf cellular medicines for severe inflammatory conditions, with additional therapies in development for various indications. The company has a robust global intellectual property portfolio and proprietary manufacturing processes to ensure availability of cell therapies worldwide. Mesoblast is listed on the ASX and Nasdaq.



Read more at GlobeNewswire: Mesoblast Allogeneic Cell Therapy Products Are Designated